Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Natera
Advertisement
Natera Validates Signatera for Lymphoma MRD Assessment
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
Natera and Angiex Partner to Track AGX101 Response
Austin, Texas – August 27, 2026 Natera and Angiex have entered a new collaboration to assess treatment response to...
Natera, Inc. and Kupando Therapeutics Launch Phase 1 Study to Monitor ctDNA in Advanced Skin Cancers
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
Advertisements
Natera Submits Signatera to Japan PMDA for MIBC Approval
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
Natera Reports Signatera Superior to AMERK in MCC Monitoring
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
Natera Begins SIGNAL-ER 101 Trial for MRD-Guided Breast Cancer Therapy
AUSTIN, Texas — May 27, 2026 Natera, Inc. announced the enrollment of the first patients in the SIGNAL-ER 101...
Natera Advances Precision Oncology With New Austin Sequencing Hub
Austin, Texas, USA – May 21, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision medicine,...
Advertisement
